Innovent Biologics (HKEX: 01801) announced that its Phase 1b clinical trial of mazdutide injection met its primary endpoint in Chinese ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE